SCHEMBL1820485

SCHEMBL1820485

O=C(O)c1ccc(F)c(Cl)c1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.54
SRD5A2 P31213 2/20 0.53
TSHR P16473 2/20 0.48
ALOX15 P16050 1/20 0.48
FNTA P49354 2/20 0.44
FNTB P49356 2/20 0.44
MAPK1 P28482 1/20 0.44
CASP1 P29466 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CES2 O00748 2/20 0.41
CES1 P23141 2/20 0.41
HPGD P15428 1/20 0.40
LTC4S Q16873 1/20 0.39
GRIK1 P39086 1/20 0.39
SERPINE1 P05121 1/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4551433 0.81 NR4A1 (0.62) NR4A1SRD5A2TSHRALOX15FNTA
SCHEMBL29583954 0.81 NR4A1 (0.62) NR4A1SRD5A2TSHRALOX15FNTA
SCHEMBL1468587 0.78 SRD5A2 (0.61) NR4A1SRD5A2TSHRALOX15MAPK1
SCHEMBL18249795 0.77 NR4A1 (0.61) NR4A1SRD5A2TSHRALOX15FNTA
SCHEMBL26231300 0.76 NR4A1 (0.50) NR4A1SRD5A2TSHRALOX15FNTA
SCHEMBL109128 0.75 TSHR (0.48) NR4A1TSHRALOX15CASP1SMN1; SMN2
SCHEMBL1822747 0.75 NR4A1 (0.62) NR4A1SRD5A2TSHRALOX15FNTA
SCHEMBL1819626 0.75 NR4A1 (0.62) NR4A1SRD5A2TSHRALOX15FNTA
SCHEMBL29872036 0.74 NR4A1 (0.49) NR4A1SRD5A2TSHRALOX15FNTA
SCHEMBL20446219 0.74 NR4A1 (0.49) NR4A1SRD5A2TSHRALOX15FNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2960233-B1 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECH LTD (GB) 2019-10-30 EP disclosed
US-10414726-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-09-17 US disclosed
US-10414726-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-09-17 US disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20180118684-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-03 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-20160355478-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-12-08 US disclosed
US-9358222-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-07 US disclosed
EP-2960233-A1 NEW THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2015-12-30 EP disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US disclosed
US-8618158-B2 Therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-12-31 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
US-20110224274-A1 New Therapeutic Agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-09-15 US disclosed
EP-2315749-A2 NEW THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2011-05-04 EP disclosed
WO-2009156735-A2 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194486-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885
US-20110224274-A1 New Therapeutic Agents TP53, MDM2, TP53BP1 NR4A1 2295/4885SRD5A2 3329/4885TSHR 1980/4885
US-20180118684-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885
US-10414726-B2 Therapeutic agents TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885
US-20160355478-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 NR4A1 2664/4885SRD5A2 3092/4885TSHR 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.